The Burden of Chronic Hepatitis C in China From 2004 to 2050: An Individual‐Based Modeling Study
- 18 December 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 69 (4) , 1442-1452
Abstract
The launch of novel direct‐acting antivirals (DAAs) is expected to substantially reduce the burden of HCV in China. However, the effect of these changes has not yet been modeled in China. Therefore, we aim to predict the burden of HCV‐related diseases in China by simulating different scenarios that incorporate recent therapeutic advances of HCV and China's current screening strategy. We developed an individual‐based microsimulation Markov model that simulated the disease progression of HCV‐infected patients in China from 2004 to 2050. We simulated 4 scenarios with different assumptions about treatment including a natural history scenario, a pre‐DAAs scenario, a DAAs (≥F3) scenario, and a DAAs (≥F0) scenario. The introduction of DAAs is predicted to have great impacts on the burden of HCV in China, particularly under the DAAs (≥F0) scenario in which we rapidly expand DAAs to all HCV‐infected patients (≥F0) in 2021. Under this scenario, the prevalence of chronic HCV is expected to peak at 10.75 million (95% CI: 8.30‐12.85 million) around 2020 and then decrease to 7.92 million (95% CI: 5.41‐10.08 million) in 2050. Conclusion If the future increasing burden of HCV‐related diseases is to be averted, China needs to start launching the novel DAA treatment and rapidly increase the number of treated. However, to maximize the benefits of new DAAs, expanded screening is necessary to identify more cases that require treatment in the short term. Without these changes, the HCV burden in China will remain high in the future.Keywords
Funding Information
- National Natural Science Foundation of China (U1611264)
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases (491010*A61803)
This publication has 35 references indexed in Scilit:
- The Cost-Effectiveness of Birth Cohort Screening for Hepatitis C Antibody in US Primary Care SettingsGastroenterology, 2013
- State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3Value in Health, 2012
- HIV testing in community settings in resource‐rich countries: a systematic review of the evidenceHIV Medicine, 2012
- Impact of the introduction of rapid HIV testing in the Voluntary Counselling and Testing sites network of Catalonia, SpainInternational Journal of STD & AIDS, 2010
- Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosisJournal of Hepatology, 2010
- A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C VirusClinical Gastroenterology and Hepatology, 2010
- Sustained virological response to interferon plus ribavirin reduces liver‐related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus†Hepatology, 2009
- Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infectionHepatology, 2008
- Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced FibrosisAnnals of Internal Medicine, 2007
- Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patientsJournal of Hepatology, 2004